SI3390395T1 - Spojine uporabne kot inhibitorji kinaz - Google Patents

Spojine uporabne kot inhibitorji kinaz

Info

Publication number
SI3390395T1
SI3390395T1 SI201630920T SI201630920T SI3390395T1 SI 3390395 T1 SI3390395 T1 SI 3390395T1 SI 201630920 T SI201630920 T SI 201630920T SI 201630920 T SI201630920 T SI 201630920T SI 3390395 T1 SI3390395 T1 SI 3390395T1
Authority
SI
Slovenia
Prior art keywords
kinase inhibitors
compounds useful
compounds
useful
kinase
Prior art date
Application number
SI201630920T
Other languages
English (en)
Inventor
Nicolas Guisot
Original Assignee
Loxo Oncology, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB1522245.8A external-priority patent/GB201522245D0/en
Priority claimed from GBGB1613945.3A external-priority patent/GB201613945D0/en
Application filed by Loxo Oncology, Inc. filed Critical Loxo Oncology, Inc.
Publication of SI3390395T1 publication Critical patent/SI3390395T1/sl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D231/38—Nitrogen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/4155—1,2-Diazoles non condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/08—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing alicyclic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Transplantation (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
SI201630920T 2015-12-16 2016-12-16 Spojine uporabne kot inhibitorji kinaz SI3390395T1 (sl)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
GBGB1522245.8A GB201522245D0 (en) 2015-12-16 2015-12-16 Compounds useful as kinase inhibitors
GBGB1613945.3A GB201613945D0 (en) 2016-08-15 2016-08-15 Compounds useful as kinase inhibitors
PCT/GB2016/053968 WO2017103611A1 (en) 2015-12-16 2016-12-16 Compounds useful as kinase inhibitors
EP16816363.2A EP3390395B1 (en) 2015-12-16 2016-12-16 Compounds useful as kinase inhibitors

Publications (1)

Publication Number Publication Date
SI3390395T1 true SI3390395T1 (sl) 2020-11-30

Family

ID=57590725

Family Applications (1)

Application Number Title Priority Date Filing Date
SI201630920T SI3390395T1 (sl) 2015-12-16 2016-12-16 Spojine uporabne kot inhibitorji kinaz

Country Status (36)

Country Link
US (7) US10695323B2 (sl)
EP (2) EP3782994A1 (sl)
JP (3) JP6731483B2 (sl)
KR (2) KR20210018530A (sl)
CN (9) CN114634447A (sl)
AU (4) AU2016373530B2 (sl)
CA (1) CA3008488C (sl)
CL (1) CL2018001591A1 (sl)
CO (1) CO2018006164A2 (sl)
CR (1) CR20180367A (sl)
CY (1) CY1123561T1 (sl)
DK (1) DK3390395T3 (sl)
EA (1) EA035132B1 (sl)
ES (1) ES2828431T3 (sl)
FI (1) FIC20240004I1 (sl)
FR (1) FR24C1009I1 (sl)
HK (1) HK1263254A1 (sl)
HR (1) HRP20201835T1 (sl)
HU (2) HUE051921T2 (sl)
IL (4) IL285976B2 (sl)
LT (1) LT3390395T (sl)
MA (2) MA55064A (sl)
MD (1) MD3390395T2 (sl)
MX (2) MX2021003478A (sl)
NL (1) NL301262I2 (sl)
NZ (1) NZ743553A (sl)
PE (3) PE20181449A1 (sl)
PH (1) PH12018501268A1 (sl)
PT (1) PT3390395T (sl)
RS (1) RS60982B1 (sl)
SG (2) SG11201805044WA (sl)
SI (1) SI3390395T1 (sl)
TN (1) TN2018000213A1 (sl)
UA (2) UA122258C2 (sl)
WO (1) WO2017103611A1 (sl)
ZA (4) ZA201804137B (sl)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201410430D0 (en) 2014-06-11 2014-07-23 Redx Pharma Ltd Compounds
CN108431007B (zh) 2015-09-16 2022-06-07 洛克索肿瘤学股份有限公司 用于治疗癌症的作为btk抑制剂的吡唑并嘧啶衍生物
SG11201805044WA (en) 2015-12-16 2018-07-30 Loxo Oncology Inc Compounds useful as kinase inhibitors
GB201801226D0 (en) 2018-01-25 2018-03-14 Redx Pharma Plc Modulators of Rho-associated protein kinase
CN112313224B (zh) * 2018-04-06 2024-08-13 阿尔托斯实验室公司 Atf6抑制剂和其用途
CN112119063B (zh) 2018-05-18 2023-10-17 富士胶片株式会社 3-二氟甲基吡唑化合物的制造方法及3-二氟甲基吡唑-4-羧酸化合物的制造方法以及吡唑烷化合物
EP3829543A1 (en) * 2018-07-31 2021-06-09 Loxo Oncology, Inc. Spray-dried dispersions and formulations of (s)-5-amino-3-(4-((5-fluoro-2-methoxybenzamido)methyl)phenyl)-1-(1,1,1-trifluoro propan-2-yl)-1h-pyrazole-4-carboxamide
EP4010333A1 (en) 2019-08-09 2022-06-15 Kalvista Pharmaceuticals Limited Plasma kallikrein inhibitors
WO2021053234A1 (en) * 2019-09-19 2021-03-25 Johann Wolfgang Goethe-Universität Frankfurt am Main Compounds and compositions for treating kidney disease
CN110724135B (zh) * 2019-11-18 2023-04-28 上海医药工业研究院有限公司 一种艾拉普林中间体及其制备方法
WO2021113497A1 (en) * 2019-12-06 2021-06-10 Loxo Oncology, Inc. Dosing of a bruton's tyrosine kinase inhibitor
EP4118086A1 (en) * 2020-03-12 2023-01-18 Fochon Biosciences, Ltd. Compounds useful as kinase inhibitors
TW202317099A (zh) 2020-09-10 2023-05-01 美商絡速藥業公司 用於製備(s)-5-胺基-3-(4-((5-氟-2-甲氧基苯甲醯胺基)甲基)苯基)-1-(1,1,1-三氟丙烷-2-基)-1h-吡唑-4-甲醯胺之方法及中間體
CN112386597B (zh) * 2020-10-15 2022-03-15 天津济坤医药科技有限公司 泽布替尼在制备治疗肺纤维化疾病药物中的应用
WO2022140246A1 (en) 2020-12-21 2022-06-30 Hangzhou Jijing Pharmaceutical Technology Limited Methods and compounds for targeted autophagy
WO2022228302A1 (en) * 2021-04-25 2022-11-03 Bionova Pharmaceuticals (Shanghai) Limited Heteroaromatic carboxamide compounds and its use
JP2024517963A (ja) 2021-05-14 2024-04-23 ロクソ オンコロジー， インコーポレイテッド ブルトン型チロシンキナーゼ阻害剤の共結晶形態
AU2022303441A1 (en) * 2021-07-01 2024-01-25 Hangzhou Healzen Therapeutics Co., Ltd. Bruton's tyrosine kinase and mutant degrader, composition and application thereof
CN115611810A (zh) * 2021-07-16 2023-01-17 深圳市塔吉瑞生物医药有限公司 取代的吡唑类化合物及包含该化合物的组合物及其用途
WO2023110970A1 (en) 2021-12-14 2023-06-22 Netherlands Translational Research Center Holding B.V Macrocyclic btk inhibitors
WO2023143355A1 (en) * 2022-01-28 2023-08-03 Hansoh Bio Llc Azacycle amide derivative, preparation methods and medicinal uses thereof
WO2023174397A1 (en) * 2022-03-18 2023-09-21 Insilico Medicine Ip Limited Pyrazole membrane-associated tyrosine-and threonine-specific cdc2-inhibitory kinase (pkmyt1) inhibitors and uses thereof
CN115894376A (zh) * 2022-12-15 2023-04-04 南京雷正医药科技有限公司 一种芳香族酰胺类化合物、药物组合物及其用途
WO2024176164A1 (en) 2023-02-22 2024-08-29 Assia Chemical Industries Ltd. Solid state form of pirtobrutinib

Family Cites Families (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CZ2002936A3 (cs) 1999-09-17 2002-10-16 Abbott Gmbh & Co. Kg Pyrazolopyrimidiny jako terapeutické prostředky
US6921763B2 (en) 1999-09-17 2005-07-26 Abbott Laboratories Pyrazolopyrimidines as therapeutic agents
US6291504B1 (en) * 1999-10-20 2001-09-18 Dupont Pharmaceuticals Company Acylsemicarbazides and their uses
US20030225098A1 (en) 2002-03-21 2003-12-04 Hirst Gavin C. Kinase inhibitors
MX347525B (es) 2006-09-22 2017-04-27 Pharmacyclics Llc Inhibidores de tirosina cinasa de bruton.
CA2665214A1 (en) * 2006-10-06 2008-05-29 Abbott Laboratories Novel imidazothiazoles and imidazoxazoles
US8987233B2 (en) 2006-11-03 2015-03-24 Pharmacyclics, Inc. Bruton's tyrosine kinase activity probe and method of using
EP2560007A1 (en) 2007-03-28 2013-02-20 Pharmacyclics, Inc. Identification of bruton's tyrosine kinase inhibitors
KR20110025224A (ko) 2008-06-27 2011-03-09 아빌라 테라퓨틱스, 인크. 헤테로아릴 화합물 및 이의 용도
US8338439B2 (en) 2008-06-27 2012-12-25 Celgene Avilomics Research, Inc. 2,4-disubstituted pyrimidines useful as kinase inhibitors
JP5369183B2 (ja) 2008-07-16 2013-12-18 ファーマサイクリックス，インク． 固形腫瘍の治療用のブルートンのチロシンキナーゼの阻害剤
WO2010010154A1 (en) * 2008-07-24 2010-01-28 Nerviano Medical Sciences S.R.L. 3,4-diarylpyrazoles as protein kinase inhibitors
US8426428B2 (en) 2008-12-05 2013-04-23 Principia Biopharma, Inc. EGFR kinase knockdown via electrophilically enhanced inhibitors
US7718662B1 (en) * 2009-10-12 2010-05-18 Pharmacyclics, Inc. Pyrazolo-pyrimidine inhibitors of bruton's tyrosine kinase
EP2575818A4 (en) 2010-06-03 2013-11-06 Pharmacyclics Inc USE OF INHIBITORS OF BRUTON TYROSINE KINASE (BTK)
TWI532737B (zh) 2010-06-30 2016-05-11 艾諾屋製藥公司 可溶性鳥苷酸環化酶（ｓＧＣ）刺激物
MX347040B (es) 2011-05-17 2017-04-10 Principia Biopharma Inc Inhibidores de tirosina-cinasas.
AU2012255759B2 (en) 2011-05-17 2017-08-10 Principia Biopharma, Inc. Kinase inhibitors
JP2014520863A (ja) 2011-07-13 2014-08-25 ファーマサイクリックス，インク． Ｂｒｕｔｏｎ型チロシンキナーゼの阻害剤
EP2548877A1 (en) 2011-07-19 2013-01-23 MSD Oss B.V. 4-(5-Membered fused pyridinyl)benzamides as BTK-inhibitors
US8377946B1 (en) 2011-12-30 2013-02-19 Pharmacyclics, Inc. Pyrazolo[3,4-d]pyrimidine and pyrrolo[2,3-d]pyrimidine compounds as kinase inhibitors
CA2874461C (en) 2012-06-18 2021-10-12 Principia Biopharma Inc. Formulations containing reversible covalent compounds
US9572811B2 (en) 2012-08-03 2017-02-21 Principia Biopharma Inc. Treatment of dry eye
GEP201706748B (en) * 2012-08-10 2017-10-10 Boehringer Ingelheim Int Heteroaromatic compounds as bruton's tyrosine kinase (btk) inhibitors
GB201214750D0 (en) * 2012-08-17 2012-10-03 Respivert Ltd Compounds
AU2013340345B2 (en) * 2012-11-02 2016-10-27 Pfizer Inc. Bruton's tyrosine kinase inhibitors
CN103848810A (zh) * 2012-11-30 2014-06-11 北京赛林泰医药技术有限公司 鲁顿酪氨酸激酶抑制剂
US8957080B2 (en) 2013-04-09 2015-02-17 Principia Biopharma Inc. Tyrosine kinase inhibitors
GB201309085D0 (en) 2013-05-20 2013-07-03 Redx Pharma Ltd Compounds
RS60934B1 (sr) * 2013-09-30 2020-11-30 Guangzhou Innocare Pharma Tech Co Ltd Supstituisani nikotinimidni inhibitori btk i njihova priprema i upotreba u lečenju karcinoma, inflamatorne i autoimune bolesti
WO2015075051A1 (en) * 2013-11-19 2015-05-28 Universitaet Des Saarlandes Allosteric inhibitors of atypical protein kinases c
EP3082809B1 (en) 2013-12-20 2021-01-20 Merck Sharp & Dohme Corp. Btk inhibitors
CA2939186C (en) 2014-02-21 2023-03-07 Principia Biopharma Inc. Salts and solid form of a btk inhibitor
GB201404987D0 (en) * 2014-03-20 2014-05-07 Redx Pharma Ltd Compounds
CN105085474B (zh) * 2014-05-07 2018-05-18 北京赛林泰医药技术有限公司 鲁顿酪氨酸激酶抑制剂
GB201410430D0 (en) * 2014-06-11 2014-07-23 Redx Pharma Ltd Compounds
MX2017009831A (es) 2015-01-28 2017-11-02 Bayer Pharma AG Derivados de 4h-pirrol[3,2-c]piridin-4-ona.
GB2548542A (en) * 2015-06-16 2017-09-27 Redx Pharma Plc Compounds
JO3633B1 (ar) 2015-09-16 2020-08-27 Katholieke Univ Leuven Ku Leuven Research & Development مشتقات اندول مستبدلة احاديا او ثنائيا بصفتها مانعات للتكاثر الفيروسي لحمى الفنك
CN108431007B (zh) 2015-09-16 2022-06-07 洛克索肿瘤学股份有限公司 用于治疗癌症的作为btk抑制剂的吡唑并嘧啶衍生物
JOP20160198B1 (ar) 2015-09-16 2022-03-14 Janssen Pharmaceuticals Inc مشتقات اندول مستبدلة احاديا او ثنائيا بصفتها مانعات للتكاثر الفيروسي لحمى الفنك
JP6856662B2 (ja) 2015-12-16 2021-04-07 プライオスター プロプライアタリー リミティド デンドリマー及びその製剤
EP3390400B1 (en) 2015-12-16 2021-01-20 Bristol-Myers Squibb Company Heteroarylhydroxypyrimidinones as agonists of the apj receptor
HRP20211845T1 (hr) 2015-12-16 2022-03-04 Boehringer Ingelheim International Gmbh Derivati bipirazolila korisni za liječenje autoimunih bolesti
AU2016369505B2 (en) 2015-12-16 2019-08-15 Ecolab Usa Inc. Peroxyformic acid compositions for membrane filtration cleaning
SG11201805044WA (en) 2015-12-16 2018-07-30 Loxo Oncology Inc Compounds useful as kinase inhibitors

Also Published As

Publication number Publication date
MA49809A1 (fr) 2021-08-31
KR102215792B1 (ko) 2021-02-16
FR24C1009I1 (fr) 2024-05-24
IL276283B (en) 2021-03-25
UA127863C2 (uk) 2024-01-31
EP3390395A1 (en) 2018-10-24
EP3390395B1 (en) 2020-09-09
HRP20201835T1 (hr) 2021-01-08
CN114573510A (zh) 2022-06-03
JP7419437B2 (ja) 2024-01-22
CA3008488C (en) 2023-10-10
AU2021225162B2 (en) 2023-08-03
LT3390395T (lt) 2020-11-25
IL276283A (en) 2020-09-30
US20180362512A1 (en) 2018-12-20
ZA202100544B (en) 2023-06-28
PE20220507A1 (es) 2022-04-07
IL281067B (en) 2022-04-01
JP2022120013A (ja) 2022-08-17
CN114634447A (zh) 2022-06-17
EA035132B1 (ru) 2020-04-30
EP3782994A1 (en) 2021-02-24
ZA202107472B (en) 2023-03-29
US20190000806A1 (en) 2019-01-03
MX2021003478A (es) 2022-07-25
AU2016373530A1 (en) 2018-07-05
US20210093611A1 (en) 2021-04-01
JP7086140B2 (ja) 2022-06-17
US10342780B2 (en) 2019-07-09
PE20181449A1 (es) 2018-09-12
AU2021225162A1 (en) 2021-09-30
MX2018007267A (es) 2018-11-09
JP2018538307A (ja) 2018-12-27
IL285976B2 (en) 2023-10-01
CN113603645A (zh) 2021-11-05
RS60982B1 (sr) 2020-11-30
ZA202107471B (en) 2023-03-29
JP2020172535A (ja) 2020-10-22
JP6731483B2 (ja) 2020-07-29
IL259923A (en) 2018-07-31
PE20220502A1 (es) 2022-04-07
KR20210018530A (ko) 2021-02-17
EA201891268A1 (ru) 2018-11-30
CN114621146A (zh) 2022-06-14
IL285976A (en) 2021-10-31
NL301262I2 (nl) 2024-04-24
MA55064A (fr) 2021-09-29
CL2018001591A1 (es) 2018-09-28
IL281067A (en) 2021-04-29
CN108473481A (zh) 2018-08-31
NZ743553A (en) 2022-08-26
CO2018006164A2 (es) 2018-09-20
SG11201805044WA (en) 2018-07-30
US11826351B2 (en) 2023-11-28
US20190135762A1 (en) 2019-05-09
SG10202012498TA (en) 2021-01-28
ZA201804137B (en) 2022-08-31
AU2016373530B2 (en) 2021-01-21
AU2021201811A1 (en) 2021-04-22
KR20180115261A (ko) 2018-10-22
CN113636978A (zh) 2021-11-12
WO2017103611A1 (en) 2017-06-22
UA122258C2 (uk) 2020-10-12
FIC20240004I1 (fi) 2024-03-01
ES2828431T3 (es) 2021-05-26
HUE051921T2 (hu) 2021-03-29
HK1263254A1 (zh) 2020-02-21
CN114716381A (zh) 2022-07-08
US20230372298A1 (en) 2023-11-23
CY1123561T1 (el) 2022-03-24
CA3008488A1 (en) 2017-06-22
HUS2400003I1 (hu) 2024-03-28
MD3390395T2 (ro) 2021-02-28
PH12018501268A1 (en) 2019-02-18
PT3390395T (pt) 2020-11-03
US10695323B2 (en) 2020-06-30
AU2021225161B2 (en) 2023-08-03
US10464905B2 (en) 2019-11-05
AU2021225161A1 (en) 2021-09-30
IL285976B1 (en) 2023-06-01
CN114591242A (zh) 2022-06-07
US20220062239A1 (en) 2022-03-03
CR20180367A (es) 2018-11-12
US20200276162A1 (en) 2020-09-03
DK3390395T3 (da) 2020-09-28
US10918622B2 (en) 2021-02-16
IL259923B (en) 2020-08-31
BR112018012341A2 (pt) 2018-12-04
CN108473481B (zh) 2022-04-19
AU2021201811B2 (en) 2022-01-27
CN114605327A (zh) 2022-06-10
US11471441B2 (en) 2022-10-18
TN2018000213A1 (en) 2019-10-04

Similar Documents

Publication Publication Date Title
HUS2400003I1 (hu) Kináz inhibitorként alkalmas vegyületek
ZA201700115B (en) Aminopyridazinone compounds as protein kinase inhibitors
LT3371190T (lt) Heterocikliniai junginiai, kaip pi3k-gama inhibitoriai
IL268614A (en) Aminotriazolopyridines as kinase inhibitors
IL255750A (en) Heterocyclic compounds as kinase inhibitors
IL274207A (en) Aminoimidazopyridazines as kinase inhibitors
IL266150A (en) Amide compounds as kinase inhibitors
IL266789A (en) Heterocyclic compounds as kinase inhibitors
EP3102571A4 (en) SUBSTITUTED PYRIMIDINES USEFUL AS EGFR-T790M KINASE INHIBITORS
HK1253576A1 (zh) 作為mnk抑制劑的吡咯並嘧啶化合物
GB201613945D0 (en) Compounds useful as kinase inhibitors
GB201522245D0 (en) Compounds useful as kinase inhibitors
GB201519381D0 (en) Kinase inhibitors
GB201519382D0 (en) Kinase inhibitors